fiacitabine
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000981)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetMETHYLATING AGENT
methylating agent
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2F)cc1I- Mol. weight
- 371.11 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL272557 ↗
Also known as
- 1-(2-fluoro-2-deoxy-beta-d-arabinofuranosyl)-5-iodocytosine
- 2(1h)-pyrimidinone, 4-amino-1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-iodo-
- 2'-deoxy-2'-fluoro-beta-arabinofuranosyl-5-iodocytosine
- 2'-fluoro-5-iodo-1-beta-d-arabinofuranosylcytosine
- 2'-fluoro-5-iodo-aracytosine
- fiac
- fiac
- fiac
- fiacitabine
- fiacitabine
- fiacitabine
- fiacitabine
- fiacitabine
- fiacitabine, (alpha-d)-isomer
- fiacitabine monohydrochloride
- fiacitabine monohydrochloride, 2-(14)c-labeled
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000981 | Phase 2 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), Oclassen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1999 |
| Oclassen | For profit | 1 | 0 | 1 | 1999 |
2 organizations
Page 1 / 1